Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.
You may also be interested in...
Melanoma Approvals Break New Ground In Immunotherapy
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.
Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos
Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.